Associations among Plasma Concentrations of Edoxaban and M-4, Prothrombin Time, and the SLCO1B1*15 Haplotype in Patients With Nonvalvular Atrial Fibrillation.

Junichi Nakagawa, Takahiko Kinjo, Naoya Aiuchi, Kayo Ueno, Hirofumi Tomita, Takenori Niioka

Therapeutic drug monitoring   45 ( 3 )   409 - 416   2023.6

Effect of pregnane X receptor and cytochrome P450 oxidoreductase gene polymorphisms on trough concentrations of rivaroxaban and edoxaban in patients with nonvalvular atrial fibrillation.

Junichi Nakagawa, Takahiko Kinjo, Naoya Aiuchi, Kayo Ueno, Hirofumi Tomita, Takenori Niioka

European journal of clinical pharmacology   79 ( 5 )   703 - 705   2023.5

服薬に対するネガティブな意識が服薬アドヒアランスに及ぼす影響 岩木健康増進プロジェクト健診調査報告

工藤 正純, 今 良仁, 横山 智士, 金澤 佐知子, 小原 信一, 細井 一広, 照井 一史, 中川 潤一, 阿保 成慶, 津山 博匡, 兵藤 塁, 相内 尚也, 世永 早紀, 畑山 昂大, 川口 聖也, 伊藤 梢, 島田 美智子, 金城 育代[成田], 井原 一成, 中路 重之, 新岡 丈典

医薬品相互作用研究   47 ( 1 )   10 - 18   2023.3

Impact of solute carrier transporter gene polymorphisms on serum creatinine concentrations in healthy volunteers.

Satoshi Yokoyama, Junichi Nakagawa, Masakiyo Kudo, Naoya Aiuchi, Tatsuya Seito, Mizuri Isida, Tatsuya Mikami, Kazushige Ihara, Shigeyuki Nakaji, Takenori Niioka

Pharmacology research & perspectives   11 ( 1 )   e01048   2023.2

Impacts of pregnane X receptor and cytochrome P450 oxidoreductase gene polymorphisms on trough concentrations of apixaban in patients with non-valvular atrial fibrillation.

Junichi Nakagawa, Takahiko Kinjo, Naoya Aiuchi, Kayo Ueno, Hirofumi Tomita, Takenori Niioka

European journal of clinical pharmacology   79 ( 1 )   127 - 135   2023.1

Impact of trimethoprim on serum creatinine, sodium, and potassium concentrations in patients taking trimethoprim-sulfamethoxazole without changes in glomerular filtration rate.

Satoshi Yokoyama, Junichi Nakagawa, Naoya Aiuchi, Tatsuya Seito, Takenori Niioka

Journal of clinical pharmacy and therapeutics   47 ( 9 )   1409 - 1417   2022.9

Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole.

Naoya Aiuchi, Junichi Nakagawa, Hirotake Sakuraba, Takenori Takahata, Kosuke Kamata, Norihiro Saito, Kayo Ueno, Masahiro Ishiyama, Kazufumi Yamagata, Hiroyuki Kayaba, Takenori Niioka

Pharmacology research & perspectives   10 ( 2 )   e00935   2022.4

免疫抑制剤TDM実施において考慮すべき点

三浦 昌朋, 見野 靖晃, 本間 真人, 新岡 丈典, 竹内 裕紀

日本臨床腎移植学会雑誌   9 ( 2 )   149 - 156   2021.12

Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.

Junichi Nakagawa, Takahiko Kinjo, Mei Iizuka, Kayo Ueno, Hirofumi Tomita, Takenori Niioka

Basic & clinical pharmacology & toxicology   128 ( 2 )   297 - 304   2021.2

Evaluation for pharmacokinetic exposure of cytotoxic anticancer drugs in elderly patients receiving (R-)CHOP therapy.

Junichi Nakagawa, Takenori Takahata, Rui Hyodo, Yu Chen, Kengo Hasui, Kota Sasaki, Kensuke Saito, Kayo Ueno, Kazuhiro Hosoi, Kazufumi Terui, Atsushi Sato, Takenori Niioka

Scientific reports   11 ( 1 )   785 - 785   2021.1

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.

Hisashi Tanaka, Kageaki Taima, Tomonori Makiguchi, Junichi Nakagawa, Takenori Niioka, Sadatomo Tasaka

Cancer communications (London, England)   41 ( 1 )   83 - 87   2021.1

注射用抗がん薬使用状況調査に基づく医療費削減のためのdrug vial optimization実施方法に関する検討

照井 一史, 兵藤 塁, 中川 潤一, 細井 一広, 小原 信一, 本間 聖明, 明石 真弓, 佐藤 和洋, 矢田 康司, 宮崎 晃臣, 田中 南美英, 神 雅昭, 中村 一成, 山本 章二, 田村 健悦, 新岡 丈典

日本病院薬剤師会雑誌 = Journal of Japanese Society of Hospital Pharmacists   56 ( 12 )   1445 - 1451   2020.12

Cyclosporine protects from intestinal epithelial injury by modulating butyrate uptake via upregulation of membrane monocarboxylate transporter 1 levels.

Shinji Ota, Hirotake Sakuraba, Hiroto Hiraga, Shukuko Yoshida, Miwa Satake, Yui Akemoto, Nahoko Tanaka, Rina Watanabe, Maeda Takato, Yasuhisa Murai, Kayo Ueno, Takenori Niioka, Makoto Hayakari, Yoh Ishiguro, Shinsaku Fukuda

Biochemistry and biophysics reports   24   100811 - 100811   2020.12

注射用抗がん薬使用状況調査に基づく医療費削減のためのdrug vial optimization実施方法に関する検討

照井 一史, 兵藤 塁, 中川 潤一, 細井 一広, 小原 信一, 本間 聖明, 明石 真弓, 佐藤 和洋, 矢田 康司, 宮崎 晃臣, 田中 南美英, 神 雅昭, 中村 一成, 山本 章二, 田村 健悦, 新岡 丈典

日本病院薬剤師会雑誌   56 ( 12 )   1445 - 1451   2020.12

Relationship Between Change Rate of Tacrolimus Clearance During Continuous Intravenous Infusion and Recipient Recovery at an Early Stage After Living Donor Liver Transplantation.

Junichi Nakagawa, Keinosuke Ishido, Yuka Tono, Norihisa Kimura, Taiichi Wakiya, Yuji Okamura, Kenichi Hakamada, Takenori Niioka

European journal of drug metabolism and pharmacokinetics   45 ( 5 )   619 - 626   2020.10

3系統以上の抗菌薬に耐性を示す緑膿菌サーベイランスにおけるAntibiotic Heterogeneity Indexの有用性に関する検討

東野 優花, 岡村 祐嗣, 津山 博匡, 井上 文緒, 齋藤 紀先, 萱場 広之, 新岡 丈典

日本病院薬剤師会雑誌 = Journal of Japanese Society of Hospital Pharmacists   56 ( 7 )   791 - 796   2020.7

3系統以上の抗菌薬に耐性を示す緑膿菌サーベイランスにおけるAntibiotic Heterogeneity Indexの有用性に関する検討

東野 優花, 岡村 祐嗣, 津山 博匡, 井上 文緒, 齋藤 紀先, 萱場 広之, 新岡 丈典

日本病院薬剤師会雑誌   56 ( 7 )   791 - 796   2020.7

Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer.

Mitsuji Nagahama, Tomoko Ozeki, Akifumi Suzuki, Kiminori Sugino, Takenori Niioka, Koichi Ito, Masatomo Miura

Medical oncology (Northwood, London, England)   36 ( 5 )   39 - 39   2019.3

Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients With Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide.

Kobayashi Takahiro, Miura Masatomo, Niioka Takenori, Abumiya Maiko, Ito Fumiko, Kobayashi Isuzu, Ikeda Sho, Yoshioka Tomoko, Kameoka Yoshihiro, Takahashi Naoto

Ther Drug Monit   40 ( 3 )   301 - 309   2018.6

The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma.

Kobayashi Takahiro, Miura Masatomo, Abumiya Maiko, Niioka Takenori, Kanno Shuichi, Takahashi Naoto

Ann Hematol   97 ( 6 )   1097 - 1099   2018.6

Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients.

Numakura Kazuyuki, Fujiyama Nobuhiro, Takahashi Makoto, Igarashi Ryoma, Tsuruta Hiroshi, Maeno Atsushi, Huang Mingguo, Saito Mitsuru, Narita Shintaro, Inoue Takamitsu, Satoh Shigeru, Tsuchiya Norihiko, Niioka Takenori, Miura Masatomo, Habuchi Tomonori

Oncotarget   9 ( 38 )   25277 - 25284   2018.5

Influence of CYP3A5 genetic differences in tacrolimus on quantitative interstitial fibrosis and long-term graft function in kidney transplant recipients.

Komine Naoki, Satoh Shigeru, Saito Mitsuru, Numakura Kazuyuki, Inoue Takamitsu, Tsuruta Hiroshi, Narita Shintaro, Komatsuda Atsushi, Nanjo Hiroshi, Kagaya Hideaki, Niioka Takenori, Miura Masatomo, Mitobe Yoko, Habuchi Tomonori

Int Immunopharmacol   58   57 - 63   2018.5

Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients.

Kagaya Hideaki, Niioka Takenori, Saito Mitsuru, Inoue Takamitsu, Numakura Kazuyuki, Yamamoto Ryohei, Akamine Yumiko, Habuchi Tomonori, Satoh Shigeru, Miura Masatomo

Int J Mol Sci   19 ( 3 )   2018.3

Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.

Igarashi Ryoma, Inoue Takamitsu, Fujiyama Nobuhiro, Tsuchiya Norihiko, Numakura Kazuyuki, Kagaya Hideaki, Saito Mitsuru, Narita Shintaro, Satoh Shigeru, Niioka Takenori, Miura Masatomo, Habuchi Tomonori

Med Oncol   35 ( 4 )   51 - 51   2018.3

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia.

Mita Akiko, Abumiya Maiko, Miura Masatomo, Niioka Takenori, Takahashi Saori, Yoshioka Tomoko, Kameoka Yoshihiro, Takahashi Naoto

Exp Hematol Oncol   7   9 - 9   2018

Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes.

Niioka Takenori, Fujishima Naohito, Abumiya Maiko, Yamashita Takaya, Ubukawa Kumi, Nara Miho, Fujishima Masumi, Takahashi Naoto, Miura Masatomo

Ther Drug Monit   39 ( 5 )   514 - 521   2017.10

Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation.

Kagaya Hideaki, Niioka Takenori, Saito Mitsuru, Inoue Takamitsu, Numakura Kazuyuki, Habuchi Tomonori, Satoh Shigeru, Miura Masatomo

Xenobiotica   47 ( 10 )   916 - 922   2017.10

Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.

Niioka Takenori, Kagaya Hideaki, Saito Mitsuru, Inoue Takamitsu, Numakura Kazuyuki, Yamamoto Ryohei, Habuchi Tomonori, Satoh Shigeru, Miura Masatomo

Clin Exp Nephrol   21 ( 5 )   787 - 796   2017.10

Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.

Okuda Yuji, Sato Kazuhiro, Sudo Kazuhisa, Hasegawa Yukiyasu, Asano Mariko, Miura Hajime, Takeda Masahide, Sano Masaaki, Watanabe Hiroyuki, Kobayashi Hiroyuki, Niioka Takenori, Miura Masatomo, Ito Hiroshi

Cancer Chemother Pharmacol   79 ( 5 )   1013 - 1020   2017.5

Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.

Numakura Kazuyuki, Tsuchiya Norihiko, Kagaya Hideaki, Takahashi Makoto, Tsuruta Hiroshi, Inoue Takamitsu, Narita Shintaro, Huang Mingguo, Satoh Shigeru, Niioka Takenori, Miura Masatomo, Habuchi Tomonori

Anticancer Drugs   28 ( 1 )   97 - 103   2017.1

Quantification of Interstitial Fibrosis in Renal Allografts and Clinical Correlates of Long-Term Graft Function.

Nara Mizuho, Komatsuda Atsushi, Numakura Kazuyuki, Saito Mitsuru, Inoue Takamitsu, Niioka Takenori, Miura Masatomo, Mitobe Yoko, Okuyama Shin, Takahashi Naoto, Habuchi Tomonori, Satoh Shigeru

Am J Nephrol   46 ( 3 )   187 - 194   2017

Therapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis.

Kobayashi Takahiro, Niioka Takenori, Miura Masatomo, Takahashi Naoto

Ann Hematol   95 ( 12 )   2087 - 2088   2016.12

Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.

Yamashita Takaya, Fujishima Naohito, Miura Masatomo, Niioka Takenori, Abumiya Maiko, Shinohara Yoshinori, Ubukawa Kumi, Nara Miho, Fujishima Masumi, Kameoka Yoshihiro, Tagawa Hiroyuki, Hirokawa Makoto, Takahashi Naoto

Cancer Chemother Pharmacol   78 ( 1 )   111 - 118   2016.7

Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib.

Kobayashi Hiroyuki, Sato Kazuhiro, Niioka Takenori, Takeda Masahide, Okuda Yuji, Asano Mariko, Ito Hiroshi, Miura Masatomo

Med Oncol   33 ( 6 )   57 - 57   2016.6

Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients.

Niioka Takenori, Kagaya Hideaki, Saito Mitsuru, Inoue Takamitsu, Numakura Kazuyuki, Yamamoto Ryohei, Akamine Yumiko, Habuchi Tomonori, Satoh Shigeru, Miura Masatomo

Int J Urol   23 ( 6 )   484 - 490   2016.6

Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease.

Togashi Masaru, Niioka Takenori, Komatsuda Atsushi, Nara Mizuho, Okuyama Shin, Omokawa Ayumi, Abumiya Maiko, Wakui Hideki, Takahashi Naoto, Miura Masatomo

Eur J Clin Pharmacol   71 ( 9 )   1091 - 1097   2015.9

Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer.

Kobayashi Hiroyuki, Sato Kazuhiro, Niioka Takenori, Miura Hajime, Ito Hiroshi, Miura Masatomo

Clin Lung Cancer   16 ( 4 )   274 - 281   2015.7

Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation.

Niioka Takenori, Kagaya Hideaki, Saito Mitsuru, Inoue Takamitsu, Numakura Kazuyuki, Habuchi Tomonori, Satoh Shigeru, Miura Masatomo

Int J Mol Sci   16 ( 1 )   1840 - 1854   2015.1

Effects of CYP3A5 polymorphism and the tacrolimus 12 h concentration on tacrolimus-induced acute renal dysfunction in patients with lupus nephritis.

Niioka Takenori, Komatsuda Atsushi, Kato Shotaro, Togashi Masaru, Okuyama Shin, Omokawa Ayumi, Nara Mizuho, Wakui Hideki, Takahashi Naoto, Miura Masatomo

Xenobiotica   45 ( 12 )   1147 - 1153   2015

Characterization of clinical and genetic risk factors associated with dyslipidemia after kidney transplantation.

Numakura Kazuyuki, Kagaya Hideaki, Yamamoto Ryohei, Komine Naoki, Saito Mitsuru, Hiroshi Tsuruta, Akihama Susumu, Inoue Takamitsu, Narita Shintaro, Tsuchiya Norihiko, Habuchi Tomonori, Niioka Takenori, Miura Masatomo, Satoh Shigeru

Dis Markers   2015   179434 - 179434   2015

Pharmacokinetic and CYP3A5 pharmacogenetic differences between once- and twice-daily tacrolimus from the first dosing day to 1 year after renal transplantation.

Satoh Shigeru, Niioka Takenori, Kagaya Hideaki, Numakura Kazuyuki, Inoue Takamitsu, Saito Mitsuru, Komine Naoki, Narita Shintaro, Tsuchiya Norihiko, Habuchi Tomonori, Miura Masatomo

Pharmacogenomics   15 ( 11 )   1495 - 1506   2014.8

A limited sampling model to estimate exposure to lenalidomide in multiple myeloma patients.

Shida Seiji, Takahashi Naoto, Miura Masatomo, Niioka Takenori, Matsumoto Morio, Hagihara Masao, Kobayashi Takahiro, Abumiya Maiko, Kameoka Yoshihiro, Fujishima Naohito, Tagawa Hiroyuki, Hirokawa Makoto, Sawada Kenichi

Ther Drug Monit   36 ( 4 )   505 - 509   2014.8

Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib.

Takahashi Naoto, Miura Masatomo, Kuroki Jun, Mitani Kinuko, Kitabayashi Atsushi, Sasaki Osamu, Kimura Hideo, Imai Kiyotoshi, Tsukamoto Norifumi, Noji Hideyoshi, Kondo Takeshi, Motegi Mutsuhito, Kato Yuichi, Mita Masayuki, Saito Hajime, Yoshida Chikashi, Torimoto Yoshihiro, Kimura Tomofumi, Wano Yuji, Nomura Jun, Yamamoto Satoshi, Mayama Ko, Honma Riko, Sugawara Tomohiro, Sato Shinji, Shinagawa Atsushi, Abumiya Maiko, Niioka Takenori, Harigae Hideo, Sawada Kenichi

Biomark Res   2 ( 1 )   6 - 6   2014.3

A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib.

Miura Masatomo, Sato Kazuhiro, Miura Hajime, Niioka Takenori, Kobayashi Hiroyuki, Narita Chihiro, Ito Hiroshi

Ther Drug Monit   36 ( 1 )   24 - 29   2014.2

Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.

Hinai Y, Motoyama S, Niioka T, Miura M

J Clin Pharm Ther   38 ( 6 )   498 - 503   2013.12

Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients.

Niioka Takenori, Kagaya Hideaki, Miura Masatomo, Numakura Kazuyuki, Saito Mitsuru, Inoue Takamitsu, Habuchi Tomonori, Satoh Shigeru

Eur J Clin Pharmacol   69 ( 9 )   1659 - 1665   2013.9

A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction.

Shinohara Yoshinori, Takahashi Naoto, Nishiwaki Kaichi, Hino Masayuki, Kashimura Makoto, Wakita Hisashi, Hatano Yoshiaki, Hirasawa Akira, Nakagawa Yasuaki, Itoh Kuniaki, Masuoka Hidekazu, Aotsuka Nobuyuki, Matsuura Yasuhiro, Takahara Sinobu, Sano Koji, Kuroki Jun, Hata Tomoko, Nakamae Hirohisa, Mugitani Atsuko, Nakane Takahiko, Miyazaki Yasushi, Niioka Takenori, Miura Masatomo, Sawada Kenichi

Haematologica   98 ( 9 )   1407 - 1413   2013.9

Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants.

Nara Miho, Takahashi Naoto, Miura Masatomo, Niioka Takenori, Kagaya Hideaki, Fujishima Naohito, Saitoh Hirobumi, Kameoka Yoshihiro, Tagawa Hiroyuki, Hirokawa Makoto, Sawada Kenichi

Eur J Clin Pharmacol   69 ( 6 )   1321 - 1329   2013.6

A limited sampling strategy to estimate the area under the concentration-time curve of tacrolimus modified-release once-daily preparation in renal transplant recipients.

Niioka Takenori, Miura Masatomo, Kagaya Hideaki, Saito Mitsuru, Numakura Kazuyuki, Habuchi Tomonori, Satoh Shigeru

Ther Drug Monit   35 ( 2 )   228 - 232   2013.4

Study on improvement of the accuracy and precision of predicted plasma concentration of vancomycin in the administration planning support for children

Itagaki Shirou, Hayakari Makoto, Kudo Masakiyo, Niioka Takenori, Uchiyama Michiko, Kanazawa Sachiko, Hosoi Kazuhiro, Terui Kazufumi, Kojima Keiya, Yasujima Minoru

Hirosaki Medical Journal   64 ( 1 )   58 - 64   2013

Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.

Niioka Takenori, Satoh Shigeru, Kagaya Hideaki, Numakura Kazuyuki, Inoue Takamitsu, Saito Mitsuru, Narita Shintaro, Tsuchiya Norihiko, Habuchi Tomonori, Miura Masatomo

Transplantation   94 ( 10 )   1013 - 1019   2012.11

H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia.

Matsuoka Akihito, Takahashi Naoto, Miura Masatomo, Niioka Takenori, Kawakami Kimihiro, Matsunaga Takuya, Sawada Kenichi

Cancer Chemother Pharmacol   70 ( 2 )   351 - 352   2012.8

Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation.

Takahashi Naoto, Miura Masatomo, Scott Stuart A, Niioka Takenori, Sawada Kenichi

J Hematol Oncol   5   23 - 23   2012.5

Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers.

Saruwatari Junji, Yasui-Furukori Norio, Niioka Takenori, Akamine Yumiko, Takashima Ayaka, Kaneko Sunao, Uno Tsukasa

J Clin Psychopharmacol   32 ( 2 )   195 - 199   2012.4

Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.

Takahashi Naoto, Miura Masatomo, Niioka Takenori, Sawada Kenichi

Cancer Chemother Pharmacol   69 ( 4 )   999 - 1004   2012.4

Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients.

Kagaya Hideaki, Miura Masatomo, Niioka Takenori, Saito Mitsuru, Numakura Kazuyuki, Habuchi Tomonori, Satoh Shigeru

Antimicrob Agents Chemother   56 ( 2 )   825 - 829   2012.2

Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation.

Miura Masatomo, Niioka Takenori, Kato Shoutaro, Kagaya Hideaki, Saito Mitsuru, Habuchi Tomonori, Satoh Shigeru

Ther Drug Monit   33 ( 3 )   295 - 302   2011.6

Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation.

Miura M, Niioka T, Kagaya H, Saito M, Hayakari M, Habuchi T, Satoh S

J Clin Pharm Ther   36 ( 2 )   208 - 216   2011.4

Clinical usefulness of limited sampling strategies for estimating AUC of proton pump inhibitors.

Niioka Takenori

Yakugaku Zasshi   131 ( 3 )   407 - 413   2011.3

Influence of CYP2C19 and ABCB1 polymorphisms on plasma concentrations of lansoprazole enantiomers after enteral administration.

Miura Masatomo, Motoyama Satoru, Hinai Yudai, Niioka Takenori, Endo Masahiro, Hayakari Makoto, Ogawa Jun-ichi

Xenobiotica   40 ( 9 )   630 - 636   2010.9

Correlation between R/S enantiomer ratio of lansoprazole and CYP2C19 activity after single oral and enteral administration.

Miura Masatomo, Motoyama Satoru, Hinai Yudai, Niioka Takenori, Hayakari Makoto, Ogawa Jun-ichi, Suzuki Toshio

Chirality   22 ( 7 )   635 - 640   2010.7

Optimal Dose of Levofloxacin in Elderly Patients with Streptococcus Pneumoniae Infection Based on Monte Carlo Simulation

Okamura Yuji, Niioka Takenori, Kimura Masahiko, Yasujima Minoru, Hayakari Makoto

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)   36 ( 8 )   592 - 598   2010

CYP2C19 genotype-based (R)-warfarin disposition assessment: some views on data analysis.

Niioka Takenori, Uno Tsukasa

J Clin Pharm Ther   34 ( 5 )   611 - 612   2009.10

Early phase limited sampling strategy characterizing tacrolimus and mycophenolic acid pharmacokinetics adapted to the maintenance phase of renal transplant patients.

Miura Masatomo, Satoh Shigeru, Niioka Takenori, Kagaya Hideaki, Saito Mitsuru, Hayakari Makoto, Habuchi Tomonori, Suzuki Toshio

Ther Drug Monit   31 ( 4 )   467 - 474   2009.8

Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations.

Fujii Akira, Yasui-Furukori Norio, Nakagami Taku, Niioka Takenori, Saito Manabu, Sato Yasushi, Kaneko Sunao

Drug Des Devel Ther   2   139 - 144   2009.2

Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers.

Niioka Takenori, Miura Masatomo, Uno Tsukasa, Yasui-Furukori Norio, Hayakari Makoto, Tateishi Tomonori, Suzuki Toshio

Eur J Clin Pharmacol   64 ( 5 )   503 - 509   2008.5

Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients.

Miura Masatomo, Satoh Shigeru, Niioka Takenori, Kagaya Hideaki, Saito Mitsuru, Hayakari Makoto, Habuchi Tomonori, Suzuki Toshio

Ther Drug Monit   30 ( 1 )   52 - 59   2008.2

Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration.

Niioka Takenori, Uno Tsukasa, Sugimoto Katsuyoshi, Sugawara Kazunobu, Hayakari Makoto, Tateishi Tomonori

Eur J Clin Pharmacol   63 ( 11 )   1031 - 1038   2007.11

Simultaneous determination of warfarin enantiomers and its metabolite in human plasma by column-switching high-performance liquid chromatography with chiral separation.

Uno Tsukasa, Niioka Takenori, Hayakari Makoto, Sugawara Kazunobu, Tateishi Tomonori

Ther Drug Monit   29 ( 3 )   333 - 339   2007.6

Different serum concentrations of steady-state valproic acid in two sustained-release formulations.

Yasui-Furukori Norio, Saito Manabu, Nakagami Taku, Niioka Takenori, Sato Yasushi, Fujii Akira, Kaneko Sunao

Psychiatry Clin Neurosci   61 ( 3 )   308 - 312   2007.6

Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.

Niioka Takenori, Uno Tsukasa, Yasui-Furukori Norio, Takahata Takenori, Shimizu Mikiko, Sugawara Kazunobu, Tateishi Tomonori

Cancer Chemother Pharmacol   59 ( 5 )   575 - 580   2007.4

Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters.

Yasui-Furukori Norio, Saito Manabu, Niioka Takenori, Inoue Yoshimasa, Sato Yasushi, Kaneko Sunao

Ther Drug Monit   29 ( 1 )   45 - 48   2007.2

Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.

Uno Tsukasa, Niioka Takenori, Hayakari Makoto, Yasui-Furukori Norio, Sugawara Kazunobu, Tateishi Tomonori

Eur J Clin Pharmacol   63 ( 2 )   143 - 149   2007.2

Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects.

Yasui-Furukori Norio, Saito Manabu, Inoue Yoshimasa, Niioka Takenori, Sato Yasushi, Tsuchimine Shoko, Kaneko Sunao

Eur J Clin Pharmacol   63 ( 1 )   51 - 56   2007.1

Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve.

Niioka Takenori, Uno Tsukasa, Yasui-Furukori Norio, Shimizu Mikiko, Sugawara Kazunobu, Tateishi Tomonori

Eur J Clin Pharmacol   62 ( 10 )   855 - 861   2006.10

Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.

Niioka Takenori, Yasui-Furukori Norio, Uno Tsukasa, Sugawara Kazunobu, Kaneko Sunao, Tateishi Tomonori

Ther Drug Monit   28 ( 3 )   321 - 325   2006.6

Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes.

Shimizu Mikiko, Uno Tsukasa, Niioka Takenori, Yaui-Furukori Norio, Takahata Takenori, Sugawara Kazunobu, Tateishi Tomonori

J Chromatogr B Analyt Technol Biomed Life Sci   832 ( 2 )   241 - 248   2006.3

Hepatic clearance improves after angioplasty of the hepatic vein.

Narumi S, Hakamada K, Toyoki Y, Totsuka E, Niioka T, Umehara Y, Ono H, Nishimura A, Yoshihara S, Sasaki M

Transplant Proc   36 ( 10 )   3091 - 3092   2004.12

消化器外科領域における至適抗菌剤使用に関する検討

鳴海 俊治, 新岡 丈典, 袴田 健一, 吉原 秀一, 小田桐 弘毅, 川崎 仁司, 十束 英志, 豊木 嘉一, 森田 隆幸, 佐々木 睦男

日本消化器外科学会雑誌   36 ( 7 )   2003.7

Relation between Kidney Function and Use Trend of Renal Excreted Agents on Inpatients of Digestive Organ Surgery in Hirosaki University Hospital

NIIOKA Takenori, TAKEUCHI Hiroyuki, NARUMI Shunji, KAWASAKI Hitoshi, HAKAMADA Kenichi, ODAGIRI Hiroki, MORITA Takayuki, SASAKI Mutsuo, SATO Junya, SUGAWARA Kazunobu

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)   27 ( 4 )   399 - 405   2001.8

臨床への薬物動態学

猪爪信夫，岩川精吾，上野和行，加藤美紀，黒沢菜穗子，齊藤嘉津彦，菅原和信，戸田貴大，豊口禎子，灘井雅行，新岡丈典，長谷川高明，平田純生，福島昭二，和田育男，渡邊真知子，渡辺善照．（ Role： Joint author）

廣川書店  2009.4